CNS drug design: balancing physicochemical properties for optimal brain exposure.

The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins. Designing molecules that can overcome this protection system and achieve optimal concentration at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery. Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochemical properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates. This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most critical physicochemical and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chemistry strategies toward molecules with optimal brain exposure. A summary of modern CNS pharmacokinetic concepts and methods is also provided.

[1]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[2]  James S. Scott,et al.  Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice. , 2014, Journal of medicinal chemistry.

[3]  G. Pasternak,et al.  Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. , 1989, The Journal of pharmacology and experimental therapeutics.

[4]  Paul W Smith,et al.  The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. , 2010, Bioorganic & medicinal chemistry letters.

[5]  Xingrong Liu,et al.  Rational use of plasma protein and tissue binding data in drug design. , 2014, Journal of medicinal chemistry.

[6]  P. Jeffrey,et al.  Challenges for blood–brain barrier (BBB) screening , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[8]  M. Shalaeva,et al.  High throughput method for the indirect detection of intramolecular hydrogen bonding. , 2014, Journal of medicinal chemistry.

[9]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[10]  Wei Liu,et al.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.

[11]  M. Wigglesworth,et al.  Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders. , 2010, Journal of medicinal chemistry.

[12]  Thomas J. Raub,et al.  In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.

[13]  Anders Tunek,et al.  High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. , 2007, Journal of medicinal chemistry.

[14]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[15]  Xingrong Liu,et al.  Strategies to optimize brain penetration in drug discovery. , 2005, Current opinion in drug discovery & development.

[16]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[17]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[18]  Eyassu Chernet,et al.  Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. , 2005, Life sciences.

[19]  R. Béliveau,et al.  Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.

[20]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[21]  P. Roepe,et al.  The P-Glycoprotein Efflux Pump: How Does it Transport Drugs? , 1998, The Journal of Membrane Biology.

[22]  Thomas J. Raub,et al.  Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier , 2009, Drug Metabolism and Disposition.

[23]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Yuan Cheng,et al.  Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid. , 2012, Journal of medicinal chemistry.

[25]  Kelly H. Jordan,et al.  Steady-State Brain Concentrations of Antihistamines in Rats , 2004, Pharmacology.

[26]  Arup K. Ghose,et al.  Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery , 2011, ACS chemical neuroscience.

[27]  F. Berardi,et al.  Trimethoxybenzanilide-based P-glycoprotein modulators: an interesting case of lipophilicity tuning by intramolecular hydrogen bonding. , 2014, Journal of medicinal chemistry.

[28]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[29]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[30]  A. Leo,et al.  Partition coefficients and their uses , 1971 .

[31]  A. Marxer,et al.  Hypotensive hydrazinophthalazines and related compounds. , 1959, Journal of medicinal and pharmaceutical chemistry.

[32]  Jos H Beijnen,et al.  Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.

[33]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[34]  M. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[35]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[36]  M. Yliperttula,et al.  Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  P. Patsalos,et al.  The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus) , 2004, Seizure.

[38]  T. Richmond,et al.  Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect. , 1984, Journal of molecular biology.

[39]  Mark Muzi,et al.  Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data , 2006, Journal of Pharmacology and Experimental Therapeutics.

[40]  Geri A. Sawada,et al.  Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization , 2006 .

[41]  Sara Eyal,et al.  Drug interactions at the blood-brain barrier: fact or fantasy? , 2009, Pharmacology & therapeutics.

[42]  A. Reichel Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept , 2009, Chemistry & biodiversity.

[43]  Susanne Winiwarter,et al.  Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. , 2009, Journal of medicinal chemistry.

[44]  K. Bui,et al.  Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. , 2010, Bioorganic & medicinal chemistry letters.

[45]  L. Hennig,et al.  Fluorine hydrogen short contacts and hydrogen bonds in substituted benzamides , 2009 .

[46]  Kelly H. Jordan,et al.  P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. , 2003, Journal of pharmaceutical sciences.

[47]  B. Långström,et al.  Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.

[48]  Remigijus Didziapetris,et al.  Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.

[49]  Richard Morphy,et al.  The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.

[50]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[51]  Victor A. Levin,et al.  RELATIONSHIP OF OCTANOL/WATER PARTITION COEFFICIENT AND MOLECULAR WEIGHT TO RAT BRAIN CAPILLARY PERMEABILITY , 1980 .

[52]  J. Macor,et al.  Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists. , 2013, Bioorganic & medicinal chemistry letters.

[53]  J. Dobbing,et al.  THE BLOOD-BRAIN BARRIER , 1961, The Lancet.

[54]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[55]  M. Monshouwer,et al.  Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid , 2009, Drug Metabolism and Disposition.

[56]  A. Brown,et al.  Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. , 1993, Molecular pharmacology.

[57]  S-M Huang,et al.  Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position , 2013, Clinical pharmacology and therapeutics.

[58]  B. Walther,et al.  Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. , 2012, Journal of pharmaceutical sciences.

[59]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[60]  Z. Rankovic,et al.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.

[61]  R Griffiths,et al.  Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. , 1988, Journal of medicinal chemistry.

[62]  Giulia Caron,et al.  Integrating intramolecular hydrogen bonding (IMHB) considerations in drug discovery using ΔlogP as a tool. , 2013, Journal of medicinal chemistry.

[63]  S. Hitchcock,et al.  Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.

[64]  E. D. De Lange Utility of CSF in translational neuroscience , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[65]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[66]  J. Pandit,et al.  Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. , 2012, ACS medicinal chemistry letters.

[67]  Richard Svensson,et al.  Impact of Stereospecific Intramolecular Hydrogen Bonding on Cell Permeability and Physicochemical Properties , 2014, Journal of medicinal chemistry.

[68]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[69]  T. Tsuruo,et al.  The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier , 2000, Brain Research.

[70]  Markus Piel,et al.  Positron emission tomography in CNS drug discovery and drug monitoring. , 2014, Journal of medicinal chemistry.

[71]  J. Scherrmann,et al.  Elevated concentrations of morphine 6‐beta‐D‐glucuronide in brain extracellular fluid despite low blood–brain barrier permeability , 1999, British journal of pharmacology.

[72]  Paul D Leeson,et al.  Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.

[73]  P. Jeffrey,et al.  Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. , 2006, Journal of pharmaceutical sciences.

[74]  M. Danhof,et al.  Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. , 2011, Journal of pharmaceutical sciences.

[75]  T. Terasaki,et al.  Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. , 2011, Journal of pharmaceutical sciences.

[76]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[77]  T. Maurer,et al.  RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE , 2005, Drug Metabolism and Disposition.

[78]  S. McCleary,et al.  Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. , 2001, Journal of medicinal chemistry.

[79]  S. Kobayashi,et al.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Michael H. Abraham,et al.  Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .

[81]  L. Di,et al.  Demystifying brain penetration in central nervous system drug discovery. Miniperspective. , 2013, Journal of medicinal chemistry.

[82]  Paul W Smith,et al.  New quinoline NK3 receptor antagonists with CNS activity. , 2009, Bioorganic & medicinal chemistry letters.

[83]  Ernesto Callegari,et al.  Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding , 2005, Journal of Pharmacology and Experimental Therapeutics.

[84]  Gary M Pollack,et al.  Fexofenadine Brain Exposure and the Influence of Blood-Brain Barrier P-Glycoprotein After Fexofenadine and Terfenadine Administration , 2009, Drug Metabolism and Disposition.

[85]  U. Bredberg,et al.  In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids , 2007, Drug Metabolism and Disposition.

[86]  Tanja Eisenblätter,et al.  A new multidrug resistance protein at the blood-brain barrier. , 2002, Biochemical and biophysical research communications.

[87]  E. Hu,et al.  Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A). , 2013, Journal of medicinal chemistry.

[88]  Christel A. S. Bergström,et al.  Absorption classification of oral drugs based on molecular surface properties. , 2003, Journal of medicinal chemistry.

[89]  K. Luthman,et al.  Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.

[90]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Reversible Michael additions: covalent inhibitors and prodrugs. , 2012, Mini reviews in medicinal chemistry.

[92]  U. Bickel,et al.  Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[93]  R. Daneman,et al.  The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.

[94]  Stina Syvänen,et al.  On The Rate and Extent of Drug Delivery to the Brain , 2007, Pharmaceutical Research.

[95]  Iain Martin,et al.  Prediction of blood-brain barrier penetration: are we missing the point? , 2004, Drug discovery today.

[96]  François Bouzom,et al.  Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach , 2013, The AAPS Journal.

[97]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[98]  D. Debruyne Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses , 1997, Clinical pharmacokinetics.

[99]  M. Kansy,et al.  Hydrogen-Bonding Capacity and Brain Penetration , 1992, Chimia (Basel).

[100]  Ian A. Watson,et al.  Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. , 2013, Molecular pharmaceutics.

[101]  Q. Smith Carrier-Mediated Drug Transport at the Blood-Brain Barrier and the Potential for Drug Targeting to the Brain , 1995 .

[102]  A. Gilbert,et al.  Targeted Covalent Enzyme Inhibitors , 2012 .

[103]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[104]  J. McKinzie,et al.  In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. , 2007, Life sciences.

[105]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[106]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[107]  É. Marsault,et al.  Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.

[108]  D. Scott,et al.  Species Independence in Brain Tissue Binding Using Brain Homogenates , 2011, Drug Metabolism and Disposition.

[109]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[110]  V. Tantishaiyakul,et al.  Prediction of Caco-2 cell permeability using partial least squares multivariate analysis. , 2001, Die Pharmazie.

[111]  Nathan Brown,et al.  Multi-objective optimization methods in drug design. , 2013, Drug discovery today. Technologies.

[112]  A. Kulkarni,et al.  A proposed screening paradigm for discovery of covalent inhibitor drugs. , 2014, Drug metabolism letters.

[113]  J. Uetrecht,et al.  New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.

[114]  Nathaniel G. Martin,et al.  Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists. , 2014, Journal of medicinal chemistry.

[115]  R N Gunn,et al.  Toward an improved prediction of human in vivo brain penetration , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[116]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[117]  M. Bock,et al.  Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists. , 2007, Journal of medicinal chemistry.

[118]  Shobha N. Bhattachar,et al.  Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. , 2011, ACS medicinal chemistry letters.

[119]  E. Jonsson,et al.  Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding , 2006, Biopharmaceutics & drug disposition.

[120]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[121]  Huichun Zhu,et al.  Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant , 2014 .

[122]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[123]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[124]  Shankar Venkatraman,et al.  Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[125]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[126]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[127]  A. Lercher Macrocyclic BACE-1 Inhibitors Acutely Reduce Aβ in Brain After Po Application. , 2010 .

[128]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[129]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[130]  B. Kuhn,et al.  Intramolecular hydrogen bonding in medicinal chemistry. , 2010, Journal of medicinal chemistry.

[131]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  P. Verhoest,et al.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.

[133]  Z. Rankovic,et al.  Designing CNS Drugs for Optimal Brain Exposure , 2015 .

[134]  C. Hansch,et al.  The parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics. , 1968, Journal of medicinal chemistry.

[135]  E. Giralt,et al.  Shuttle-mediated drug delivery to the brain. , 2011, Angewandte Chemie.

[136]  M. Lindstrom,et al.  Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition. , 2012, Bioorganic & medicinal chemistry letters.

[137]  Thomas J. Raub,et al.  How hydrogen bonds impact P-glycoprotein transport and permeability. , 2012, Bioorganic & medicinal chemistry letters.

[138]  Stephen D Pickett,et al.  The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. , 2011, Drug discovery today.

[139]  Akos Tarcsay,et al.  Impact of lipophilic efficiency on compound quality. , 2012, Journal of medicinal chemistry.

[140]  Jie Shen,et al.  Estimation of ADME Properties with Substructure Pattern Recognition , 2010, J. Chem. Inf. Model..

[141]  Daniel J. Chandler Something's got to give: psychiatric disease on the rise and novel drug development on the decline. , 2013, Drug discovery today.

[142]  Danny D Shen,et al.  Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. , 2004, Advanced drug delivery reviews.

[143]  G. Ecker,et al.  Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.

[144]  N. Shaik,et al.  P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib , 2009, Journal of Pharmacology and Experimental Therapeutics.

[145]  Matthew P. Jacobson,et al.  Predicting and improving the membrane permeability of peptidic small molecules. , 2012, Journal of medicinal chemistry.

[146]  M. Waring Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[147]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[148]  Yuichi Sugiyama,et al.  Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate , 2011, Journal of Pharmacology and Experimental Therapeutics.

[149]  Alexander Alex,et al.  Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space , 2011 .

[150]  M. Lohse,et al.  Distinct pharmacological properties of morphine metabolites at G(i)-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor. , 2011, Biochemical pharmacology.

[151]  Zoran Rankovic,et al.  CHAPTER 18:Medicinal Chemistry Challenges in CNS Drug Discovery , 2012 .

[152]  R. Béliveau,et al.  Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.

[153]  M. Potashman,et al.  Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.

[154]  Paul W Smith,et al.  Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. , 2010, Journal of medicinal chemistry.

[155]  M. Staufenbiel,et al.  Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. , 2010, Bioorganic & medicinal chemistry letters.

[156]  Osamu Okazaki,et al.  A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding , 2009, Drug Metabolism and Disposition.

[157]  M. Seelbach,et al.  Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P‐glycoprotein , 2007, Journal of neurochemistry.

[158]  N. J. Baxter,et al.  Temperature dependence of 1H chemical shifts in proteins , 1997, Journal of biomolecular NMR.

[159]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[160]  Thomas M Frimurer,et al.  Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment? , 2012, Bioorganic & medicinal chemistry letters.

[161]  T. Terasaki,et al.  Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse , 2008, Drug Metabolism and Disposition.